title: Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.
abstract: Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
authors.affiliation: Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore. drtctan@me.com
authors.forename: Ling Zhi
authors.initials: LZ
authors.lastname: Heng
authors.forename: Yujia
authors.initials: Y
authors.lastname: Chen
authors.forename: Thiam Chye
authors.initials: TC
authors.lastname: Tan
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008875:Middle Aged; D010570:Pessaries; D012008:Recurrence
chemical_list: D000935:Antifungal Agents; D007093:Imidazoles; C017125:butoconazole